Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) — Data to be Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual...
Rallybio Corporation Announces Pricing of Initial Public Offering NEW HAVEN, Conn.–(BUSINESS WIRE)–Jul. 28, 2021– Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of...
Cleerly Launches with $43 Million Series B to Provide a New Standard of Care for the Leading Cause of Death – Heart Disease Resulting from More than a Decade of Clinical Research, Company Unveils Non-Invasive Approach to Identify, and New Care Pathways to Address...
Recent Comments